New Insight into Urate-Related Mechanism of Cardiovascular Damage

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 23, 46 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

New Insight into Urate-Related Mechanism of Cardiovascular Damage

Current Pharmaceutical Design, 20(39): 6089-6095.

Author(s): Davide Grassi, Giovambattista Desideri and Claudio Ferri.

Affiliation: University of L'Aquila, Department of Life, Health, and Environmental Sciences, Viale S Salvatore, Delta, 6 Medicina, 67100 Coppito, L'Aquila, Italy.


Several experimental and clinical studies reported that hyperuricemia may trigger hypertension, metabolic syndrome, vascular damage and renal disease. Furthermore, a substantial proportion of epidemiological studies are compatible with the hypothesis that hyperuricemia may be an indipendent risk factor for cardiovascular disease as well as for an increased cardiovascular mortality. Xanthine oxidase is a critical source of reactive oxygen species contributing to vascular inflammation and endothelial dysfunction. Although a causal relationship between these conditions has not been clearly clarified, the capacity of uric acid to negatively affect vascular function by pro-oxidant effects and by decreasing nitric oxide bioavailability and consequently induce endothelial dysfunction may explain the association among hyperuricemia, hypertension, metabolic syndrome, and cardiovascular disease, also by a common mechanicistic point of view.


Uric acid, hyperuricemia, endothelial dysfunction, oxidative stress, cardiovascular risk.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 39
First Page: 6089
Last Page: 6095
Page Count: 7
DOI: 10.2174/1381612820666140417095730
Price: $58
4th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science